AMED Amedisys Inc.

Amedisys Supports New Research that Demonstrates the Value of Hospice Care Through Better Outcomes and Medicare Savings

Amedisys Supports New Research that Demonstrates the Value of Hospice Care Through Better Outcomes and Medicare Savings

BATON ROUGE, La., March 23, 2023 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice, and high-acuity care, supports the findings from the NORC at the University of Chicago study released by the National Association for Home Care & Hospice (NAHC) and the National Hospice and Palliative Care Organization (NHPCO) today that demonstrates the value of hospice care.

“This survey supports what we've long known to be true, which is that high-quality hospice care is not only the best option for patients but also a pivotal piece of driving down Medicare costs across the American healthcare system,” stated Dr. Amy Moss, Senior Vice President of Clinical Operations for Hospice at Amedisys. “We’ve seen firsthand how hospice can undeniably improve the quality of life for patients and their families at a moment when they need it most, in addition to lowering the financial and stressful burdens of end-of-life care.”

The research shows that patients’ use of hospice care contributed to $3.5 billion in savings for Medicare in 2019, while providing multiple benefits to patients, families, and caregivers. For more information, please visit .

About Amedisys:

Amedisys, Inc. is a leading healthcare at home Company delivering personalized home health, hospice, and high-acuity care services. Amedisys is focused on delivering the care that is best for our patients, whether that is home-based personal care; inpatient hospital, palliative, and skilled nursing facility (“SNF”) care in their homes; recovery and rehabilitation after an operation or injury; care focused on empowering them to manage a chronic disease; or hospice care at the end of life. More than 3,000 hospitals and 102,000 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, TN, Amedisys is a publicly held company. With approximately 20,000 employees, in 532 care centers in 37 states and the District of Columbia, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 465,000 patients in need every year, performing more than 11.2 million visits annually. For more information about the Company, please visit: .

Forward-Looking Statements: When included in this press release, words like “believes,” “belief,” “expects,” “strategy,” “plans,” “anticipates,” “intends,” “projects,” “estimates,” “may,” “might,” “could,” “would,” “should” and similar expressions are intended to identify forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are not limited to the following: changes in Medicare and other medical payment levels; changes in payments and covered services by federal and state governments; future cost containment initiatives undertaken by third-party payors; changes in the episodic versus non-episodic mix of our payors or payment methodologies; changes in the case mix of our patients; staffing shortages driven by the competitive labor market; our ability to attract and retain qualified personnel; competition in the healthcare industry; our ability to maintain or establish new patient referral sources; changes in or our failure to comply with existing federal and state laws or regulations or the inability to comply with new government regulations on a timely basis; the impact of the novel coronavirus pandemic ("COVID-19"), including the measures that have been and may be taken by governmental authorities to mitigate it, on our business, financial condition and results of operations; changes in estimates and judgments associated with critical accounting policies; our ability to consistently provide high-quality care; our ability to keep our patients and employees safe; our access to financing; our ability to meet debt service requirements and comply with covenants in debt agreements; business disruptions due to natural or man-made disasters, climate change or acts of terrorism, widespread protests or civil unrest; our ability to open care centers, acquire additional care centers and integrate and operate these care centers effectively; our ability to realize the anticipated benefits of acquisitions, investments and joint ventures; our ability to integrate, manage and keep our information systems secure; the impact of inflation; and changes in laws or developments with respect to any litigation relating to the Company, including various other matters, many of which are beyond our control.

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events. We expressly disclaim any obligation or undertaking and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law.

Contact:  
Nick Muscato

Amedisys, Inc.

Chief Strategy Officer

615.928.5452

 Kendra Kimmons

Amedisys, Inc.

Media Relations

225.299.3720



EN
23/03/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Amedisys Inc.

 PRESS RELEASE

Amedisys Reports First Quarter 2024 Financial Results

Amedisys Reports First Quarter 2024 Financial Results BATON ROUGE, La., April 24, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period ended March 31, 2024. Three-Month Periods Ended March 31, 2024 and 2023 Net service revenue increased $15.0 million to $571.4 million compared to $556.4 million in 2023. Prior year included $15.0 million of net service revenue from our personal care business which was divested on March 31, 2023.Net income attributable to Amedisys, Inc. of $14.4 million, which is inclusive of merger-relat...

 PRESS RELEASE

Amedisys Reports Fourth Quarter and Year-End 2023 Financial Results

Amedisys Reports Fourth Quarter and Year-End 2023 Financial Results BATON ROUGE, La., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period and year ended December 31, 2023. Three-Month Periods Ended December 31, 2023 and 2022 Net service revenue increased $8.8 million to $570.8 million compared to $562.0 million in 2022. Prior year included $15.9 million of net service revenue from our personal care business which was divested on March 31, 2023.Net income attributable to Amedisys, Inc. of $19.3 million, which is...

 PRESS RELEASE

Amedisys Offers Molecular Testing for Rapid and Accurate Infection Dia...

Amedisys Offers Molecular Testing for Rapid and Accurate Infection Diagnosis BATON ROUGE, La., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice and high-acuity care in the home, is now offering advanced molecular testing to its care centers nationwide. This innovative collaboration with Patient Choice Laboratories utilizes molecular testing for the swift and precise identification of pathogens in urine, respiratory and wound infections. By leveraging the latest in diagnostic technology, Amedisys aims to improve the quality of infe...

 PRESS RELEASE

Amedisys Reports Third Quarter 2023 Financial Results

Amedisys Reports Third Quarter 2023 Financial Results BATON ROUGE, La., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and nine-month periods ended September 30, 2023. Three-Month Periods Ended September 30, 2023 and 2022 Net service revenue decreased $1.8 million to $556.2 million compared to $558.0 million in 2022. Prior year included $16.6 million of net service revenue from our personal care business which was divested on March 31, 2023.Net income attributable to Amedisys, Inc. of $26.0 million compared to $25.6 mi...

 PRESS RELEASE

Amedisys Celebrates National Quality Week

Amedisys Celebrates National Quality Week Held October 15-21, this Observance Shines a Light on Our Commitment to Quality Care BATON ROUGE, La., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice and high-acuity care in the home, is proud to celebrate National Quality Week October 15-21, 2023. This week-long observance serves as an opportunity for Amedisys to recognize and highlight the organization's commitment to delivering the highest standard of quality care. During National Quality Week, Amedisys will focus on the importance...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch